Skip to content

Clinical observation on the improvement of erectile dysfunction of kidney-yang deficiency type by Eryang Wenshen Decoction

Clinical observation on the improvement of erectile dysfunction of kidney-yang deficiency type by Eryang Wenshen Decoction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001343
Enrollment
Unknown
Registered
2026-05-26
Start date
2026-01-26
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction

Interventions

control group:Tadalafil tablets (Yangling Buchang Pharmaceutical Co., Ltd., Chinese Drug Approval No. H20223823
5 mg/tablet) were administered at a dose of 5 mg once daily.
experimental group:On the basis of the control group, Eryang Wenshen Decoction was additionally administered orally. The herbal composition was as follows: prepared aconite root 6 g, cassia twig 10 g,

Sponsors

The Seventh People's Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Patients met the above diagnostic criteria for erectile dysfunction in Western medicine and the traditional Chinese medicine syndrome differentiation criteria for kidney-yang deficiency syndrome. (2)Aged 22–65 years. (3)Had a stable sexual partner and regular sexual activity. (4)Had not taken any medications that might affect the outcomes of this clinical study within 1 month before enrollment. (5)Voluntarily participated in the study and signed written informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients with anatomical abnormalities of the penis. (2)Patients with severe vasculogenic or neurogenic erectile dysfunction. (3)Patients with concomitant urinary calculi, urethritis, acute prostatitis, or other related diseases. (4)Patients with severe hepatic or renal dysfunction. (5)Patients with known allergy to any of the study medications. (6)Patients planning to conceive during the study period. (7)Patients currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
International Index of Erectile Function-5;

Secondary

MeasureTime frame
Traditional Chinese medicine syndrome score;erectile hardness assessment;Patient Health Questionnaire-9;Generalized Anxiety Disorder-7;serum sex hormone levels;audiovisual sexual stimulation;

Countries

China

Contacts

Public ContactSun Jianming

Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine

Sunjm67@126.com18930831258

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026